Ingmar Bruns

CIK: 0001838041

Transaction Breakdown

Open Market Buys (P)1 (14.3%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ZNTL

Zentalis Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

ZNTL
Zentalis Pharmaceuticals, Inc.
Sep 30, 2026
Award(A)
Direct
9.7K shares at avg. $2.18$21K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 9, 2026
Sale(S)
Direct
335 shares at avg. $2.39$801.622
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 6, 2026
Sale(S)
Direct
3K shares at avg. $2.43$7K
ZNTL
Zentalis Pharmaceuticals, Inc.
Jan 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
365K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 6, 2025
Purchase(P)
Direct
20K shares at avg. $2.28$46K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 3, 2025
Award(A)
Direct
16.6K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Dec 2, 2024
Award(A)
Stock Option (Right to Buy)
Direct
712.7K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	9,727	$2.18	$21,205	Direct
Feb 9, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	335	$2.39	$802	Direct
Feb 6, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	2,962	$2.43	$7,197	Direct
Jan 8, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	365,000	-	-	Direct
Feb 6, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Purchase(P)	20,000	$2.28	$45,656	Direct
Feb 3, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	16,629	-	-	Direct
Dec 2, 2024	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	712,650	-	-	Direct

1-7 of 7 transactions

About Bruns Ingmar

Bruns Ingmar (SEC CIK 0001838041) files insider reports with the SEC as Chief Medical Officer of Zentalis Pharmaceuticals, Inc. (ZNTL).

Signal8 holds 7 ownership filings by Bruns Ingmar (1 Form 3, 6 Form 4), filed between Nov 13, 2024 and Oct 1, 2026. Those filings report 7 transactions, from Dec 2, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bruns Ingmar's filings is in SAN DIEGO, CA.

Recent filings by Bruns Ingmar

Sep 30, 2026: Grant or award of ZNTL shares (Form 4, code A).
Feb 9, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Feb 6, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Jan 8, 2026: Grant or award of ZNTL derivative securities (Form 4, code A).
Feb 6, 2025: Open-market purchase of ZNTL shares (Form 4, code P).

Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)

WALTERS GROUP, 10% Owner
Johnson David Michael, Director
Skvarka Jan, Director
Walker Luke Nathaniel, Director
Kariuki Enoch, Director
Myers Scott Dunseth, Director

How to read Form 4 transaction codes